Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE2: Cabazitaxel and Pelvic RT in High-Risk Prostate Cancer
NCT01952223Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Dec 2013
- Primary completion
- Dec 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabazitaxel ginsenoside liposome injection in prostate cancer (PCa), sponsored by Unicancer. Started Dec 2013; status: active, not recruiting.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01952223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01952223.